Treg Isolation via CD4, CD25, CD127, and CD226 Marker Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating and isolating regulatory T cells (Treg) for adoptive cell therapies face challenges such as contamination by non-Treg cells and lineage instability during in vitro culture, necessitating improved identification and isolation techniques.
Innovation Solution
A method involving the analysis and isolation of Treg cells based on specific markers like CD4, CD25, CD226, and CD127 expression levels, allowing for the identification and isolation of cells that express CD4 and CD25, with low or no expression of CD127 and CD226, to enhance purity and suppressive capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to generate and isolate Treg cells, then Treg cells can be obtained for adoptive cell therapy, but the isolation is contaminated by non-Treg cells and exhibits lineage instability during in vitro culture
Solution Approach 1:
The patent segments the Treg cell population into distinct subsets based on marker expression profiles (CD4+, CD25+, CD127-, CD226-). By defining specific phenotypic characteristics for different Treg subsets, the method enables selective isolation of pure Treg populations without contamination from non-Treg cells, thereby resolving the contradiction between reliability and method complexity.
Solution Approach 2:
The patent utilizes changes in marker expression parameters (CD4, CD25, CD127, CD226) to identify and isolate Treg cells. By monitoring and selecting cells based on specific expression levels of these markers, the method achieves reliable Treg isolation while maintaining lineage stability during in vitro culture, avoiding contamination issues.
2Reliability
If Treg cells are isolated using conventional methods, then they can be used for therapy, but their suppressive capacity is reduced due to heterogeneity and contamination
Solution Approach 1:
The patent applies local quality by defining specific marker expression characteristics for different Treg subsets (e.g., CD4+CD25+CD127-CD226-). This allows precise identification and isolation of Treg cells with high suppressive capacity while excluding non-Treg cells, thereby improving both reliability and measurement precision simultaneously.
Solution Approach 2:
The method employs feedback through multi-marker analysis to verify Treg cell identity and purity. By assessing multiple markers (CD4, CD25, CD127, CD226) and comparing expression patterns against defined Treg subset profiles, the system ensures accurate identification and maintains high suppressive capacity while preventing contamination.
Data Source
AI summary
The invention pertains to methods of isolating a Treg from a subject, the method comprising the steps of analyzing a sample of cells obtained from the subject to determine the level of expression of polypeptides and/or polynucleotides corresponding to proteins CD 127, CD4, CD25, and CD226 and isolating, as the Treg, a cell which expresses CD4 and CD25, expresses low levels of CD 127 or does not express CD 127, and expresses low levels of CD226 or does not express CD226. The Treg isolated from a subject can be proliferated in vitro. Accordingly, the invention also provides compositions comprising Treg isolated/proliferated according to the methods of the invention and pharmaceutically acceptable carrier and/or excipient. The pharmaceutical compositions can be used to treat and/or prevent inflammation mediated disease, for example, autoimmune diseases, such as, systemic lupus erythmatosus, rheumatoid arthritis, Multiple Sclerosis, type 1 diabetes, or inflammatory bowel disease.